Knee injury
Conditions
Interventions
Control group:0.5% isobaric bupivacaine injection and 0.9% sodium chloride injection
Control group:0.5% hyperbaric bupivacaine injection and 0.9% sodium chloride injection
Trial group:0.5% isobaric bupivacaine injection and dexamethasone injection
Trial group:0.5% hyperbaric bupivacaine injection and dexamethasone injection
Sponsors
Xuancheng City People's Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Aged >= 18 years and <= 80 years at the time of screening; 2. Patients with American Society of Anesthesiologists (ASA) physical status I to III; 3. Planned for elective unilateral knee arthroscopic surgery (e.g., meniscal debridement, chondroplasty, loose body removal, etc.) under spinal anesthesia; 4. Patients who voluntarily participate in this study and sign written informed consent.
Exclusion criteria
Exclusion criteria: 1. Contraindications to spinal anesthesia: patient refusal or inability to cooperate with spinal anesthesia; local infection at the puncture site; presence of uncorrected coagulopathy or current use of anticoagulant or antiplatelet medications; severe hypovolemia, shock; known increased intracranial pressure; 2. Drug-related contraindications and confounding factors: known allergy to the study drugs (bupivacaine, dexamethasone) or their components; long-term use of glucocorticoids (continuous use for more than 1 week within the past 3 months) or immunosuppressants; long-term use of opioids (more than 3 times per week) for chronic pain management; uncontrolled diabetes mellitus (preoperative random blood glucose > 11.1 mmol/L) or diabetic peripheral neuropathy; 3. Diseases that may interfere with assessment: pre-existing neurological disorders (e.g., peripheral neuropathy, spinal cord injury, epilepsy, etc.) or cognitive dysfunction that precludes cooperation with sensory and motor assessment; severe spinal deformity (e.g., severe scoliosis), history of spinal surgery, anticipated difficulty with needle placement; 4. Other conditions: pregnant or lactating women; presence of severe cardiac, hepatic, or renal insufficiency (Child-Pugh class B or C, eGFR < 60 ml/min/1.73 m^2).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Duration of sensory block; | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood glucose levels at 2h, 24h, and 48h postoperatively;Total intravenous rescue opioid analgesic dose within 24 hours postoperatively;Resting VAS pain scores at 2h, 6h, and 24h postoperatively;Duration of motor block;Incidence of PONV (postoperative nausea and vomiting) recorded.;Onset time of sensory block;Any postoperative adverse events, such as pruritus, chills, headache, etc.;Movement VAS pain scores at 24h postoperatively;Peak sensory block level;Time to first request for analgesia; | — |
Countries
China
Contacts
Public ContactYang Yun
Xuancheng City People's Hospital
Outcome results
None listed